INTRODUCTION
cAMP signalling pathways regulate numerous critical physiological processes, including those in airway smooth muscle, the immune system and the brain. A number of families of cyclic nucleotide phosphodiesterases (PDEs) hydrolyse cAMP and thus can regulate these pathways in cells. The PDE4 cAMP-specific PDEs can be differentiated from other PDE families by sequence identity in the catalytic region of the proteins and by their ability to be inhibited by a specific class of drugs, of which rolipram o4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidinoneq is the prototype [1] [2] [3] (the nomenclature of PDE4 isoforms is outlined in [4] ). Rolipram and other specific PDE4 inhibitors have antidepressant, anti-inflammatory and smooth muscle relaxant properties in humans [3] . PDE4 enzymes are also unique in having ' signature ' regions of sequence, called upstream conserved regions (UCR1 and UCR2), located in the N-terminal third of the proteins [3, 5] .
The mammalian PDE4s are encoded by four genes (PDE4A, PDE4B, PDE4C and PDE4D), and we and other groups have Abbreviations used : BAC, bacterial artificial chromosome ; EST, expressed sequence tag ; GFP, enhanced green fluorescent protein ; IBMX, isobutylmethylxanthine ; PDE, cyclic nucleotide phosphodiesterase ; PDE4, cAMP-specific phosphodiesterase ; PKA, cAMP-dependent protein kinase ; UCR, upstream conserved region. 1 To whom correspondence should be addressed : University of Alabama at Birmingham, Comprehensive Cancer Center, WTI 520A, 1530 3rd Avenue South, Birmingham, AL 35294-3300, U.S.A. (e-mail Graeme.Bolger!ccc.uab.edu).
The nucleotide sequence data reported in this paper have been submitted to the GenBank2, DDBJ, EMBL and GSDB Nucleotide Sequence Databases under accession numbers AF202732 and AF202733. the cytosol, which was confirmed by confocal microscopic analysis of living COS7 cells transfected with a green fluorescent protein-PDE4B4 chimaera. PDE4B4 exhibited a K m for cAMP of 5.4 µM and a V max , relative to that of the long PDE4B1 isoform, of 2.1. PDE4B4 was inhibited by the prototypical PDE4 inhibitor rolipram o4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidinoneq with an IC &! of 83 nM. Treatment of COS7 cells with forskolin, to elevate cAMP levels, produced activation of PDE4B4, which was associated with the phosphorylation of PDE4B4 on Ser-56 within UCR1. The unique tissue distribution and intracellular targeting of PDE4B4 suggests that this isoform may have a distinct functional role in regulating cAMP levels in specific cell types.
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shown that additional diversity in this family is produced by alternative mRNA splicing ( [5-9,9a ] ; see [3] for a review). The use of different exons generates three groups of PDE4 isoforms : the ' long ' isoforms, which contain both UCR1 and UCR2 ; the ' short ' isoforms, which lack UCR1 but contain UCR2 ; and the ' super-short ' isoforms, which lack UCR1 and have a truncated UCR2 [3] . In many cases, the various alternatively spliced isoforms encoded by a single gene have different patterns of expression in tissues [5] [6] [7] [10] [11] [12] [13] , suggesting that they have distinct functions. In addition, the PDE4D long isoforms can be distinguished from the short isoforms by the presence of a cAMP-dependent protein kinase (PKA) phosphorylation site within UCR1, which provides a mechanism for their regulation that is unique to these long isoforms [9,9a,14-19] .
We [5, 8, 10] and other groups [20] [21] [22] have isolated complete cDNA clones encoding three different PDE4B isoforms, and have studied their tissue distribution and biochemical properties. These isoforms differ by the substitution of unique blocks of amino acids at the N-terminal ends of their respective proteins ( Figure 1A ; reviewed in [3] ). The human PDE4B1 isoform Figure 1 Structures of mRNAs and proteins encoded by the rat PDE4B gene (A) Schematic of rat PDE4B transcripts and their encoded proteins. The four dark stippled boxes indicate the unique N-terminal regions of the proteins encoded by the following cDNAs : PDE4B1 (pRPDE89 ; GenBank TM AF202732) ; PDE4B2 (GenBank TM L27058 ; [10] ) ; PDE4B3 (GenBank TM U95748 ; [8] ) ; PDE4B4 (pRPDE90 and pRPDE92 ; GenBank TM AF202733). Also shown are regions of sequences that are highly conserved in other PDE4 isoforms, including the common long form region, UCR1 and UCR2, and the catalytic region. UCR1, UCR2 and the catalytic region are in turn separated by less conserved regions of sequence, called linker region 1 (LR1) and LR2. The C-terminal region is unique to PDE4B isoforms. The PKA phosphorylation site (PKA site) is located at the beginning of UCR1. (B) Alignment of the amino acid sequences of the N-terminal regions of the four rat PDE4B isoforms. Underlined regions indicate UCR1 and UCR2. Only the first 250 amino acids of the alignment are shown, as the remaining sequence is identical with that of rat PDE4B isoforms we have described previously [8, 10] . An arrow indicates the PKA phosphorylation site, which is within the consensus sequence RRES. (C) Alignment of the amino acid sequences of the unique N-terminal regions of rat (Ra) and human (Hu) PDE4D3 and rat and mouse (Mu) PDE4B4. The PDE4D3 sequences have been published previously : GenBank TM L20970 (human ; [5] ) and GenBank TM U09457 (rat ; [9,9a] ). Vertical dashes indicate identical amino acids. Horizontal dashes indicate gaps inserted to improve the alignments. (D) Alignment of the amino acid sequences of the unique N-terminal regions of rat (Ra) PDE4B1 (top) and human (Hu) PDE4B1 (bottom). The sequence of human PDE4B1 has been described previously (pTM72 in [5] ; GenBank TM L20966). The sequence of PDE4B4 was deduced from the pRPDE89 cDNA. (E) Alignment of the nucleotide sequence of the unique 5h end of the rat PDE4B4 (pRPDE92) cDNA (capital letters) with the corresponding human genomic sequence (lower case). The human sequences correspond to nucleotides 6894-7093 of GenBank AL591487 (BAC RP11-26A10) and nucleotides 67803-67604 of GenBank AL356437 (BAC RP4-639A9), which are identical in this region. The vertical dashes indicate identity between the two sequences ; horizontal dashes indicate gaps inserted by the program to improve the alignments. The amino acid sequence of rat PDE4B4 is shown above its corresponding cDNA sequence. Also shown are the stop codons located in the human sequence.
encodes a protein of 736 amino acids [5] . A second isoform, PDE4B2, encodes a protein of 564 amino acids in humans [5, 20, 21] and rats [10, 22] . A third isoform, PDE4B3, encodes a protein of 721 amino acids [8] . Both the PDE4B2 and PDE4B3 isoforms are strongly conserved among species, with the human and rat counterparts being of identical length and sharing over 90 % amino acid sequence identity [8, 10] .
There would be considerable value in determining the full range of PDE4 isoforms that are present in mammals. This information is essential for genetic and physiological studies of these genes. For example, identification of the complete family of isoforms encoded by the PDE4B gene will be necessary in order to determine their individual contributions to the phenotype of mice with targeted mutations of the PDE4B gene [23] . It may also be of pharmacological value, as there is currently considerable interest in developing PDE4 inhibitors as therapeutic agents, particularly for lung diseases such as asthma [24] [25] [26] [27] [28] [29] . Pharmacological studies have suggested that the cell types responsible for the therapeutic effects of these drugs may have a pattern of PDE4 expression that differs from that in cells responsible for their undesirable side effects [25] [26] [27] 29] , and that the isoforms present in different tissues may have distinct sensitivities to particular PDE4 inhibitors. Identification of the full range of PDE4 isoforms, and determination of their differential expression in tissues, will be essential for understanding the molecular basis of these pharmacological effects.
We now describe the cloning of a cDNA, pRPDE90, which encodes a fourth PDE4B isoform, which we call PDE4B4. pRPDE90 was isolated from rat brain, and encodes a protein of 659 amino acids that is present in a wide spectrum of tissues, including the brain. PDE4B4 differs from other long PDE4B isoforms in that it contains a unique N-terminal region of 17 amino acids. Unlike other the long PDE4 isoforms that we have studied [7, 8, [30] [31] [32] , PDE4B4 is found exclusively in the cytosol of transfected COS7 cells. It is also more active than the long PDE4B1 isoform, indicating that its unique N-terminal region can regulate its catalytic activity. Finally, we show that PDE4B4 is phosphorylated and activated by the action of PKA.
EXPERIMENTAL Isolation and analysis of cDNA clones
Procedures were as described by Sambrook and Russell [33] , unless specified otherwise. A rat (Rattus norwegenesis ; SpragueDawley strain) cerebral cortex cDNA library, cloned into the EcoRI site of Lambda ZAPII, was obtained from Stratagene. The cDNA library was screened by hybridization with a probe corresponding to nucleotides 204 -1299 of rat PDE4B3 (GenBank TM accession number U95748 [8] ). Hybridization was performed with a final wash in 0.3iSSC\0.3 % SDS at 62 mC (1iSSC is 0.15 M NaCl, 0.015 M sodium citrate). Sequencing was performed on both strands with an ABI Prism sequencer (Perkin-Elmer) according to the manufacturer's instructions. Alignments were generated with the Gap and Lineup programs of the Wisconsin Package of UNIX sequence software programs (Oxford Molecular Group), using the standard defaults.
RNase protection analysis
This was performed exactly as we have described previously for other PDE4 isoforms [5] [6] [7] 10] . The probe designed to detect all rat PDE4B isoforms corresponds to the 3h untranslated region of the pDPD mRNA (nucleotides 1896-2112, GenBank TM accession number J04563 ; [10, 34] ). The probes specific for PDE4B3 and PDE4B4 correspond to the unique 5h ends of their mRNAs, specifically nucleotides 204 -668 of rat PDE4B3 and nucleotides 1-312 of pRPDE92 (PDE4B4).
Generation and expression of PDE4B mammalian cell expression constructs
The full open reading frame of each of rat PDE4B2 (GenBank TM accession number L27058 [10] ), PDE4B3, pRPDE89 and pRPDE90 were cloned into the NotI site of pcDNA3 (Invitrogen), placing them under the control of the cytomegalovirus intermediate early gene promoter. These constructs were prepared by the addition of NotI sites to the cDNAs by the use of PCR, as described previously [5] . A Kozak consensus site [35] was also added just upstream of the start codon. A sequence corresponding to the FLAG epitope [36] was added immediately downstream from the last codon of the PDE to encode a C-terminal fusion. The native PDE4B stop codon was removed in this process, but a synthetic stop codon was placed immediately downstream from the epitope sequence. For expression of enhanced green fluorescent protein (GFP) fusion proteins in mammalian cells, the full pRPDE90 open reading frame was cloned into the NotI site of pEGFP-C1 (Clontech) to produce a fusion between the Cterminal end of Aequorea ictoria GFP and the N-terminus of PDE4B4.
Site-directed mutagenesis
The circular mutagenesis technique [33] was used to mutate codon 56 of PDE4B4 from serine to alanine. All PCR-generated or mutagenized constructs were verified by sequencing prior to use.
Expression of cDNAs in COS7 cells
COS7 simian virus 40-transformed monkey kidney cells were grown at 37 mC in 5% CO # in Dulbecco's modified Eagle's medium supplemented with 10 % (v\v) fetal bovine serum, 2 mM glutamine and antibiotics. The cells were transfected as described previously [6, 8, 31] . In brief, the cells were grown to 70 % confluence and the medium was changed to Dulbecco's modified Eagle's medium plus 0.1 mM chloroquine. A 5 µg portion of plasmid DNA, mixed with 250 µl of 10 mg\ml DEAE-dextran in PBS, was added to the cells, and they were incubated for 4 h at 37 mC. The medium was removed and the cells were treated with 10 % (v\v) DMSO in PBS, washed once with PBS, and incubated for 48 h. In some cases (see the Results section), the transfected COS7 cells were plated into six-well plates and grown without serum overnight before being treated with various drugs.
Preparation of subcellular fractions from COS7 cells
This was performed as described previously [6, 8, 31, 32] . In brief, transfected COS7 cells were grown as above. The medium was aspirated and the cells were washed twice with ice-cold PBS, followed by a wash with ice-cold KHEM buffer [50 mM KCl, 10 mM EGTA, 1.92 mM MgCl # , 1 mM dithiothreitol, 50 mM Hepes, pH 7.2, containing Complete TM protease inhibitor cocktail (Roche Molecular Systems)], and then snap-frozen in liquid nitrogen. The frozen cells were thawed on ice and lysed by passing them 10 times through a 26.5-gauge needle. They were then centrifuged at 1000 g for 10 min to produce a low-speed pellet (P1 fraction) and a low-speed supernatant (S1). S1 was then centrifuged at 100 000 g for 60 min to produce a high-speed pellet (P2 fraction). The pellet fractions were resuspended in KHEM buffer.
Generation and characterization of antibodies
All procedures for the generation and use of PDE4B-specific antibodies were as described previously by us [8] . The M2 monoclonal antibody to the FLAG epitope [36] was obtained from Roche Molecular Systems. A polyclonal antibody (PS54-UCR1-A1) that detects the phosphoserine form of the PKA phosphorylation site, located in the UCR1 of all PDE4 long isoforms, was used as described by us previously [37] . In brief, the phosphopeptide of sequence SQRRES*FLYRSDSDYDLSP was used as antigen, and also to block the interaction of the PS54-UCR1-A1 antibody with its epitope (the phosphoserine in the peptide is indicated by *, and the PKA consensus phosphorylation site is indicated by bold type).
Immunopurification
Selective immunopurification of FLAG-tagged recombinant PDE4B4 was performed with anti-FLAG M2-agarose beads (Sigma) using procedures described by us previously in detail [37, 38] . In all cases, it was ensured that sufficient anti-FLAG antibody was present to immunoprecipitate all of the recombinant PDE4B4 in the sample, usually 50 µl of beads per 90 µg of protein from clarified cell lysates, in a total volume of 200 µl of KHEM buffer [37, 38] .
SDS/PAGE and immunoblotting
These were performed as described previously [7, 8, [30] [31] [32] . In brief, samples (2-50 µg of protein\lane) were resuspended in Laemmli buffer [39] and boiled for 5 min. Gels containing 8 % (w\v) acrylamide were run at 8 mA overnight or at 50 mA for 4 -5 h with cooling. Nitrocellulose membranes were blocked in 5 % (w\v) low-fat milk powder in TBS (10 mM Tris\HCl, pH 7.4, 150 mM NaCl) overnight at room temperature. They were then incubated with various antibodies (described above) diluted 1 : 2000 (v\v) in 1 % (w\v) low fat milk powder in TTBS (TBS plus 0.1 % Tween 20) for 3 h at room temperature. Detection of the bound antibody was performed with donkey anti-(rabbit IgG)-peroxidase antibody and the enhanced chemiluminescence system (ECL2 ; Amersham).
PDE assays
PDE activity was assayed as described previously [40] . All assays were performed at 30 mC, and a freshly prepared slurry of Dowex\ water\ethanol (1 : 1 : 1, by vol.) was used in all experiments. Initial rates were taken from linear time courses of activity. K m values were determined over a substrate range of 0.25-25 µM cAMP (10 different concentrations). Dose-dependent inhibition by rolipram was determined in the presence of 1 µM cAMP and over the range 0.1 nM-10 µM inhibitor. The IC &! was then determined from these values, using a least-squares fitting algorithm. Rolipram was dissolved in 100 % DMSO as a 1 mM stock and diluted in 20 mM Tris\HCl, pH 7.4, and 10 mM MgCl # to provide the range of concentrations used in the assay. The residual amounts of DMSO were shown not to affect PDE activity at the levels used in this study. To define K m values, data from PDE assays were analysed by computer fitting to the hyperbolic form of the Michaelis-Menten equation using an iterative least-squares procedure (Ultrafit ; with Marquardt algorithm, robust fit, experimental errors supplied ; Biosoft). V max values were calculated using the Michaelis-Menten equation and the experimentally derived K m values, as described previously [32] . As described by us previously [8, 31] , relative V max values were obtained by using equal amounts of immunoreactive PDE4B protein, as determined with PDE4B-specific antibodies in both ELISA and quantitative immunoblotting. Total PDE activity was determined at a substrate concentration of 1 µM cAMP, and was defined as the amount of PDE activity that could be inhibited by 10 µM rolipram. At this concentration, rolipram is a PDE4-selective inhibitor, and can completely inhibit PDE4 activity [3] . As we have described previously [17, 37] , in transfected COS7 cells more than 98 % of total PDE activity was due to the recombinant PDE4 enzyme.
Measurement of protein concentration
Protein concentrations were measured by the method of Bradford [41] , using BSA as a standard.
Confocal microscopy
This was performed as we have described previously [30] . Briefly, COS7 cells were seeded at 40 % confluency on to 22 mm-diameter coverslips 24 h prior to transfection. They were transfected with 2 µg of plasmid DNA using DOTAP oN-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammonium methylsulphate ; Roche Molecular Systemsq for 16 h. They were then washed, incubated in medium for a further 32 h, and then examined at room temperature with a Zeiss laser scanning confocal microscope consisting of an Axiovert 100 microscope with a i63\1.4 NA plan apochromat objective. Image analysis was carried out using the Improvision Open Lab System (Carl Zeiss).
RESULTS

Isolation of rat cDNAs encoding novel PDE4B isoforms
To search for cDNAs encoding novel PDE4 isoforms, we screened a rat brain cortex cDNA library with a probe corresponding to the unique N-terminal region, UCR1 and the majority of UCR2 of rat PDE4B3 [8] . This probe was designed to detect all long PDE4B isoforms ( Figure 1A ). cDNAs encoding
Figure 2 Tissue distribution of rat PDE4B mRNAs, as determined by RNase protection
Total RNA (10 µg) was isolated from various rat tissues and analysed by RNase protection [33] with the following probes : (A) a probe corresponding to the 3h sequence of all known PDE4B RNAs, as described previously [10] ; (B) a probe corresponding to the 5h end of PDE4B3 ; (C) a probe corresponding to the 5h end of PDE4B4. The short horizontal lines on the sides of the panels indicate size markers (in nucleotides). Open arrowheads indicate the migration of the intact probe, and filled arrowheads indicate the migration of the protected fragment. Lanes are as follows : P, probe without RNase ; 1, kidney ; 2, testis ; 3, heart ; 4, lung ; 5, spleen ; 6, liver ; 7, brainstem ; 8, cerebellum ; 9, occipital cortex ; 10, parietal cortex ; 11, temporal cortex ; 12, frontal cortex ; t, tRNA (10 µg). two different PDE4B isoforms were detected in the screen. One of these clones encoded the PDE4B1 isoform, as described in detail below. The other cDNA clone, called pRPDE90, encoded the complete open reading frame of a novel PDE4B isoform. We called this new isoform PDE4B4, using the accepted nomenclature [4] . The PDE4B4 protein consists of 659 amino acids, 16 of which are located at the extreme N-terminal end of the protein and show no detectable identity with any previously cloned PDE4B sequence ( Figure 1B) . The remaining 643 amino acids are identical with the corresponding regions of the long PDE4B isoforms PDE4B1 and PDE4B3 ( Figure 1B) . The nucleotide sequences of the common regions of PDE4B1, PDE4B3 and PDE4B4 are also identical. The sequence of the novel region of PDE4B4 was confirmed by the sequence of another clone isolated in the screen, called pRPDE92, which completely overlapped the novel region of pRPDE90 and contained sequence of an additional portion of the 5h untranslated region of the mRNA. In addition, there was strong amino acid sequence similarity between the unique N-terminal end of PDE4B4 and the corresponding unique N-terminal ends of the human and rat PDE4D3 sequences ( Figure 1C ), which provides additional evidence for the fidelity of the pRPDE90 and pRPDE92 cDNAs.
Also detected in the screen was a cDNA clone, pRPDE89, which encoded a novel protein of 736 amino acids ( Figures 1B   and 1D ). This protein was identical in length and had greater than 96 % amino acid identity (712 out of 736 amino acids) with the human PDE4B1 isoform [5] . This similarity included the unique N-terminal regions of the two proteins (90 out of 96 amino acids identical ; Figure 1D ) [5] . We therefore concluded that pRPDE89 encodes the rat PDE4B1 isoform.
Analysis of mouse DNA sequences corresponding to rat PDE4B4
In silico analysis of mouse DNA sequences in publicly available databases did not detect any cDNAs or ESTs (expressed sequence tags) that corresponded to the unique 5h end of PDE4B4. However, this analysis identified a mouse genomic sequence within the bacterial artificial chromosome (BAC) clone RP23-192K24, located on chromosome 4, that was 95 % identical at the nucleotide level with that of the unique region of pRPDE92. This mouse DNA sequence contained an open reading frame that encoded a protein sequence identical with the unique region of the rat PDE4B4 protein ( Figure 1C ). Although we have not cloned the corresponding mouse cDNA, the strong identity between these sequences suggests that an exon corresponding to that of rat PDE4B4 exists in mice. Further analysis of the RP23-192K24 clone demonstrated that it clearly contained discrete,
Figure 4 Inhibition of PDE4B4 by rolipram
A dose-response curve for the inhibition of PDE4B4 enzymic activity by rolipram was obtained, using COS7 cell extracts assayed with 1 µM cAMP as substrate. This plot is typical of data obtained with three different transfections.
widely separated blocks of sequence with high identity with the unique 5h ends of the PDE4B1 and PDE4B3 mRNAs, consistent with the concept that the respective 5h ends of the PDE4B1, PDE4B3 and PDE4B4 mRNAs are each derived from separate exons.
Analysis of human DNA sequences corresponding to rat PDE4B4
We also performed an in silico analysis of human DNA sequences available in publicly available databases. No human cDNAs or ESTs that corresponded to the unique 5h end of the pRPDE92 cDNA were detected. However, human genomic sequence that was very similar to the unique 5h end of the pRPDE92 cDNA was identified independently in two different BAC clones, RP11-26A10 and RP4-639A9 ( Figure 1E ). The RP11-26A10 BAC has also been shown to overlap two other BAC clones (RP11-360-E7 and RP4-543C6). We detected several previously known PDE4B exons in RP11-360-E7 and RP4-543C6, although these BACs have not been sequenced completely and a fully assembled contig is not available at this time. Additionally, all four BACs have been mapped by the Sanger Center (Cambridge University, Cambridge, U.K.) to chromosome 1p31-32, which we have shown previously to be the location of the human PDE4B gene [42] . Therefore we concluded that the sequences on the RP11-26A10 and RP4-639A9 BACs are located within the human PDE4B gene and correspond to the rat PDE4B4 exon.
Comparison of the human and rat PDE4B4 exons demonstrated substantial differences between their predicted proteincoding sequences ( Figure 1E ). The human DNA sequence is missing regions of sequence within a region that is otherwise highly similar to sequence that encodes the rat PDE4B4 protein.
In addition, the human sequence has tightly clustered stop codons in all three possible reading frames just upstream from the region with identity to the rat-protein-coding sequence, and only two start codons (ATG) in any reading frame downstream from the stop codons. Translation initiating at either of these start codons would not generate a biochemically active PDE4 protein. Therefore we conclude that the human PDE4B4 exon is unlikely to encode a protein. Indeed, it may not be transcribed (i.e. it could be a ' dead ' exon).
Tissue expression of PDE4B mRNAs
The tissue distributions of rat PDE4B mRNAs were determined by RNase protection. To detect transcripts specific to PDE4B3 and PDE4B4, we used probes corresponding to the unique 5h ends of the PDE4B3 and PDE4B4 mRNAs (Figures 2B and 2C) . The PDE4B3 mRNA appeared to be expressed throughout the brain, and also in heart, lung and liver, while the PDE4B4 mRNA was detected only in liver and brain. As a comparison, a single-stranded antisense RNA probe corresponding to the 3h end of the PDE4B1 isoform, which would detect all known PDE4B isoforms ( Figure 1A) , was used to probe total RNA isolated from various rat tissues (Figure 2A ). Using this probe, transcripts from the PDE4B gene were detected in a wide variety of rat tissues, consistent with results that we and others have described previously [10, 22, 34] . We have also reported previously the tissue distribution of PDE4B1 mRNA [10] .
Expression of PDE4B cDNAs in COS7 cells
We wished to determine the biochemical properties of the PDE4B4 isoform, so that they could be compared with those of the three other PDE4B isoforms that we have characterized previously [8] . As the vast majority of tissues that have been examined to date contain multiple PDE4 isoforms [43] , it is difficult to determine the enzymic properties of any individual isoform in extracts from these cells. Therefore we have developed a system in which cDNAs encoding the various isoforms are transiently expressed in COS7 cells. This allows the properties of individual recombinant PDE4 isoforms to be compared directly in the same cell background [6, 7, 31] . For this purpose, PDE4B isoforms were transiently expressed in COS7 cells from cDNAs expressed under the control of the cytomegalovirus intermediate early gene promoter.
Extracts from COS7 cells transfected with a plasmid encoding PDE4B4 were fractionated to yield low-speed (P1) and highspeed (P2) pellet fractions, along with a high-speed supernatant (S2) or cytosolic fraction, as described in the Experimental section. These fractions were then analysed by SDS\PAGE and immunoblotted with a PDE4B-specific antibody (Figure 3a) . The novel PDE4B4 isoform migrated as a single immunoreactive band of 84p4.5 kDa (n l 4 separate transfections). PDE4B4 thus migrates distinctly from the other PDE4B isoforms, namely PDE4B1 (104 kDa), PDE4B2 (78 kDa) and PDE4B3 (103 kDa ; [8] ). To confirm these data, a single immunoreactive band of 86.5p3.0 kDa was seen in PDE4B4-transfected COS7 cells upon immunoblotting with the anti-FLAG antibody, which detected the C-terminal FLAG tag incorporated into the PDE4B4 expression construct. In contrast, no immunoreactive material was identified in non-transfected or mock-transfected COS7 cells.
We have reported previously that the PDE4B1 and PDE4B3 isoforms have a molecular mass as determined by their mobility in SDS\PAGE of approx. 20 kDa greater than that predicted from their amino acid sequence [8] . This is also the case for PDE4B4, which migrates at 86 kDa in SDS\PAGE (Figure 3a) , while its predicted size on the basis of its amino acid sequence would be 73 kDa. It is possible that this may reflect particular conformational properties, or anomalous binding to SDS, of these proteins in SDS\PAGE. Similar anomalous migration in SDS\PAGE has been observed previously for recombinant and native PDE4A [7, 31] and PDE4D [6] isoforms.
When we analysed the subcellular distribution of COS7-expressed recombinant PDE4B4, we found that PDE4B4 was Figure 5 Activation of PDE4B4 by PKA (a) Immunoblots with the anti-FLAG antibody (upper) or the PS54-UCR1-A1 antibody (lower) of extracts of COS7 cells transfected to express FLAG-tagged PDE4B4. Extracts from cells treated with 100 µM forskolin plus 100 µM IBMX for 15 min are shown, along with untreated controls. Also shown is a parallel lane in which a 10-fold excess of the peptide used to make the antibody was added during immunoblotting, as a control for its specificity. The data are typical of three separate transfections. (b) COS7 cells were transfected with PDE4B4, subjected to various treatments, and then disrupted for measurement of PDE4 activity. In the bottom panel, PDE4 activity is expressed as a percentage of that present in untreated cells (ctr). Fsk, 100 µM forskolin ; IBMX, 100 µM IBMX ; H89, 0.5 µM H89. The data are shown as meanspS.D. of three different transfections. In the upper panels are immunoblots for these three conditions from typical experiments, using the anti-FLAG antibody to assess loading (top), and the PS54-UCR1-A1 antibody to assess phosphorylation (middle). (c) As for (b), but the cells were treated or not (na) for 10 min with 100 µM dibutyryl cAMP (dbcA) with or without H89. (d) COS7 cells were transfected with FLAG-tagged PDE4B4 and then treated with a combination of forskolin and IBMX for 15 min, with or without H89. They were then disrupted and PDE4B4 was immunopurified with anti-FLAG-agarose beads. PDE4 activity was then measured in the immunopurified material. In the upper panels are immunoblots for these three conditions from typical experiments, using the PS54-UCR1-A1 antibody to assess phosphorylation (top), or the anti-FLAG antibody to assess loading (middle). Each immunoblot is typical of experiments performed three times. PDE4 activity is expressed as meanpS.D. of three different transfections.
present only in the S2 fraction (Figure 3a) , while the three other PDE4B isoforms, when expressed in COS7 cells, partitioned between both the S2 and P2 fractions [8] . To obtain independent confirmation of the cytosolic location of PDE4B4, we prepared a chimaera between PDE4B4 and GFP, and expressed it in COS7 cells. The localization of the chimaera in living cells was determined by confocal microscopy. COS7 cells transfected with GFP alone showed fluorescence that was distributed throughout the cell, including the nucleus (Figure 3b) . However, COS7 cells transfected with the PDE4B4-GFP chimaera showed fluorescence throughout the cell cytosol, with clear evidence of nuclear exclusion (Figure 3b) . The fluorescence also appeared to be excluded from various vesicular structures in the transfected COS7 cells, such as the Golgi apparatus and plasma membrane. These data are consistent with the immunoblotting data showing that PDE4B4 partitions predominantly in the S2 fraction. As disruption of cells for biochemical analyses may release weakly associating membrane proteins, it is therefore reassuring to confirm the essentially cytosolic distribution of the PDE4B4 -GFP chimaera in living cells.
Enzymic properties of the novel recombinant PDE4B4 isoform
Lysates from mock-transfected (vector only) COS7 cells had a cAMP PDE activity of 9p3 pmol\min per mg of protein, which was not different from that in untransfected COS7 cells (8p3 pmol\min per mg). In contrast, lysates of COS7 cells transfected with constructs expressing PBE4B4 had a cAMP PDE activity of 529p43 pmol\min per mg (meanspS.D. ; n l 3 separate transfections). Greater than 98 % of this activity was inhibited by the PDE4-selective inhibitor rolipram (10 µM ; at a concentration of 1 µM cAMP). At least 95 % of the PDE4 activity was found in the S2 fraction (n l 5), consistent with the immunoblotting and confocal microscopy data indicating that PDE4B4 is located within the cytosol in transfected COS7 cells.
Analysis of PDE4B4 activity from the S2 fraction showed it to have a K m for cAMP of 5.4p1.0 µM (n l 4 separate transfections). We also wished to determine the V max of PDE4B4, relative to that of other PDE4B isoforms. As we have shown previously for other PDE4 isoforms [6] [7] [8] , it is possible to obtain a relative V max by normalizing for the amount of PDE4 protein in cell extracts, as measured by immunoblotting. This is possible because the various active proteins encoded by a single gene have identical catalytic regions and C-termini, and therefore can be measured by immunoblotting with antibodies to the C-terminal region of the proteins. Therefore we compared the V max of PDE4B4 with that of PDE4B1. If the V max of PDE4B1 is set at 1.0, then the relative V max of PDE4B4 was determined to be 2.1p0.2 (n l 4 separate transfections). We have shown previously that the cytosolic forms of PDE4B2 and PDE4B3 have relative V max values of 3.8 and 1.6 respectively compared with that of cytosolic PDE4B1. Thus the V max values of the two long PDE4B isoforms, i.e. PDE4B3 and PDE4B4, appear to be similar. These relative V max values assume either that the recombinant PDE4B isoforms are expressed in COS7 cells as fully functional proteins or, if as proteins with crippled activities, that the crippling of activity occurs to a similar extent for all the PDE4B isoforms. Given that these PDE4B isoforms have identical catalytic and C-terminal regions, it is most likely that recombinant active enzymes will be generated similarly in each instance.
The PDE4-selective inhibitor rolipram inhibited PDE4B4 activity with an IC &! of 83p24 nM (n l 4 separate transfections) (Figure 4 ). This compares with IC &! values of 80, 20 and 50 nM for PDE4B1, PDE4B2 and PDE4B3 respectively, as determined previously [8] . Therefore the cytosolic forms of all PDE4B isoforms appear to be inhibited similarly by rolipram.
Activation of PDE4B4 by PKA
The long PDE4D3 isoform has been shown to be activated by the phosphorylation of Ser-54 [9,9a,14-19,44] . This target serine is located within a well-defined PKA consensus phosphorylation motif, of sequence Arg-Arg-Glu-Ser, that is located at the beginning of UCR1 and which is conserved in all long PDE4 isoforms. The corresponding serine in PDE4B4 is Ser-56 ( Figure 1B) . We have developed an antibody, PS54-UCR1-A1, that recognizes this specific phosphoserine in all PDE4 isoforms ( [37, 44] ; see also the Experimental section). Using this antibody, we found no immunoreactive material in untreated COS7 cells expressing PDE4B4 (Figure 5a ). However, when these cells were treated for 15 min with the adenylate cyclase activator forskolin (100 µM) and the non-selective PDE inhibitor isobutylmethylxanthine (IBMX ; 100 µM), which together raise intracellular cAMP levels [45] , we identified a single 85 kDa immunoreactive band consistent with phosphorylated PDE4B4 (Figure 5a ). This signal was eliminated by preincubation of the antibody with the peptide used originally to generate the antibody. These data indicate that elevation of intracellular cAMP levels in COS7 cells results in phosphorylation of PDE4B4 by PKA.
We next determined whether phosphorylation of PDE4B4 affected its enzymic activity. COS7 cells were transfected with PDE4B4 and then treated with forskolin and IBMX. Extracts from these cells were then assayed for PDE4 activity. Treatment with forskolin and IBMX together produced an approx. 50 % increase in activity (Figure 5b ), which could be blocked by the PKA inhibitor H89 (0.5 µM). We estimate that any carry-over of IBMX from the cells into the PDE assays had no effect on PDE4B4 enzymic activity, as it would be diluted to less than 1 nM in the assay. These treatments consistently increased the phosphorylation of PDE4B4 at Ser-56, as demonstrated by immunoblotting with the PS54-UCR1-A1 antibody (Figure 5b) . Treatment of PDE4B4-transfected COS7 cells with the cellpermeant cAMP analogue dibutyryl cAMP (100 µM) both produced an activation of PDE4B4 similar to that seen with combined forskolin and IBMX treatment and resulted in Ser-56 phosphorylation, as demonstrated by PS54-UCR1-A1 immunoblotting (Figure 5c ). Both of these effects were ablated by the PKA inhibitor H89 (1 µM ; Figure 5c ).
Additionally, we immunopurified recombinant FLAG-tagged PDE4B4 from transfected COS7 cells using an anti-FLAG antibody (Figure 5d ). This FLAG-tagged PDE4B4 was activated similarly in COS7 cells after combined forskolin and IBMX treatment. This activation was ablated by H89 and was associated with PDE4B4 phosphorylation, as demonstrated by PS54-UCR1-A1 immunoblotting (Figure 5d ). The PDE4B4 immunopurified from cells after combined forskolin and IBMX treatment had a K m for cAMP of 4.9p0.7 µM (n l 3), similar to that of PDE4B4 isolated from untreated cells (5.1p0.8 µM; n l 3).
We conclude that the PKA-mediated phosphorylation of Ser-56 in UCR1 of PDE4B4 leads to activation of this long isoform. Consistent with this, we failed to observe any increase ( 5 % change) in the activity of a Ser-56 Ala mutant expressed in COS7 cells after treatment with a combination of forskolin and IBMX or with dibutyryl cAMP.
DISCUSSION
We describe here a novel PDE4B isoform that is expressed in multiple rat tissues, including the brain and lung. This novel isoform, which we call PDE4B4, has an N-terminal region of 17 amino acids that is not present in any other PDE4B isoform. In addition, it contains both the UCR1 and UCR2 regulatory regions, defining it as a long PDE4 isoform. It is highly likely that the PDE4B4 mRNA, like those of PDE4B1 and PDE4B3, is generated by alternative mRNA splicing and the use of separate transcriptional start sites. A similar pattern of alternative mRNA splicing generates the PDE4A and PDE4D isoforms ( [6, 7] ; see [3] for a review). The point of divergence between PDE4B1, PDE4B3 and PDE4B4 corresponds to the major point of alternative mRNA splicing in transcripts from the PDE4A [5] , PDE4B [8] and PDE4D [6,9,9a] genes and from the homologous dunce gene of Drosophila melanogaster [46] . It also corresponds to the 5h end of an exon in the human PDE4A [47] and the mouse Pde4a [48] genes. Furthermore, as there is no region of sequence common to the 5h ends of any of these cDNAs, it is likely that each is generated from a different transcriptional start site.
Although PDE4B4 is expressed in multiple rat tissues and is also likely to be present in the mouse, it does not appear to be present in humans. This result was unexpected, as almost all of the PDE4 isoforms that we have identified to date have corresponding homologues in humans and rodents [3] . In view of the conservation of the PDE4B4 sequence among rodents (mouse and rat), it is likely that PDE4B4 has an essential function in rodents. Since PDE4B4 is not present in humans, it is possible that this essential function is not required in humans or that other PDE4 isoforms, such as PDE4D3, have taken over this function in humans. This finding has implications for the extrapolation of data obtained with rodent models to humans. For example, the mouse PDE4B knockouts that have been reported to date have disruptions in exons encoding the PDE4B catalytic region, which eliminates the expression of all PDE4B isoforms in these mice [23] . The precise function of PDE4B4 could be determined by knocking out only the PDE4B4-specific exon. Since the precise contribution of PDE4B4 to the phenotype of these mice has not been determined, some caution may be appropriate in extrapolating results obtained with these mice to humans (i.e. beyond that normally encountered in comparing the two species).
PDE4B4 differs from all other PDE4 isoforms characterized previously (see [2, 3] for reviews) in that it has minimal, or no, association with cellular particulate fractions when expressed in COS7 cells. The only other known PDE4 isoforms that are essentially cytosolic when expressed in COS7 cells are the short isoforms, PDE4D1 and PDE4D2 [6] . The unique N-terminal regions of each of the various PDE4 isoforms are critical in determining their targeting to membranes, and this targeting is compatible with the interaction of the various PDE4 isoforms with different membrane anchoring proteins [2, 3] . However, we do not know the full range of anchor proteins for the PDE4s or the full pattern of expression of the anchor proteins in cells or tissues. Therefore we cannot be certain whether the lack of membrane association of PDE4B4 in COS7 cells reflects an inherent inability of PDE4B4 to associate with membranes, or is because an appropriate anchor protein is not expressed in COS7 cells, or is because some modification of PDE4B4 or its anchor is necessary for membrane association. In this regard, we and others have shown that one other long PDE4 isoform, PDE4D3, associates with different ' anchor ' proteins in different cell types [49] [50] [51] . Alternatively, it may be that PDE4B4 interacts with a soluble signalling scaffold protein, as has been shown for PDE4D5 and RACK1 (receptor for activated c-kinase), which can be isolated in a cytosolic complex [52] .
PDE4B isoforms do not appear to differ greatly with regard to V max for cAMP hydrolysis. In the present study, we showed that the maximal activity of PDE4B4 is double that of another long isoform, PDE4B1, and similar to that of the PDE4B3 isoform. The K m for cAMP of PDE4B4, 5 µM, is about double that of other PDE4B isoforms [8] . In contrast, the cytosolic forms of all long PDE4B isoforms are similarly sensitive to inhibition by rolipram, with IC &! values in the range 50-80 nM, although the short PDE4B2 isoform is more sensitive (20 nM ; [8] ). The physiological significance of these differences remains to be determined. Nonetheless, given that small changes in adenylate cyclase activity can lead to profound differences in cAMP accumulation and cell function, then the converse is likely to be true for PDEs.
Several groups, including ours, have shown that the long PDE4D3 isoform can be activated by PKA-mediated phosphorylation at Ser-54 within UCR1 [9,9a,14-19] . This serine is conserved in all PDE4 long isoforms, including those of PDE4B [3] . In the present study, we use a novel phospho-specific antiserum [37, 44] to show that elevation of cAMP levels in COS7 cells can result in phosphorylation of the corresponding serine in PDE4B4 (Ser-56). This phosphorylation is also associated with activation of PDE4B4 in a PKA-dependent fashion. It has been suggested that a physiological role for the activation of PKA phosphorylation by phosphorylation may be to contribute to cellular desensitization of cAMP signalling [1] , and it is possible that phosphorylation of PDE4B4 serves a similar role in the cells where it is expressed.
The unique N-terminal region of PDE4B4 is likely to confer specific properties on this isoform, by analogy with other PDE4 isoforms [2, 3] . These differences are likely to include its intracellular targeting, as well as its differences in V max and K m for cAMP relative to other PDE4B isoforms. These differences provide potential mechanisms for understanding the functional significance of PDE4B4 in cells and tissues. 
